Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model (Q2482986)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model |
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model |
scientific article |
Statements
Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model (English)
0 references
30 April 2008
0 references
clinical trial
0 references
discrete failure time model
0 references
missing data
0 references
potential outcomes
0 references
principal stratification
0 references
surrogate marker
0 references
0 references
0 references
0.8340351581573486
0 references
0.8246718049049377
0 references
0.8001768589019775
0 references
0.7964797616004944
0 references
